This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merck's Cancer Drug Keytruda Positive in Clinical Studies
by Zacks Equity Research
Merck & Co., Inc. (MRK) announced positive data from a phase III study KEYNOTE-024, evaluating its anti-PD-1 therapy, Keytruda (pembrolizumab) for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC).
Pfizer Provides Final Update on Phase II Talazoparib Study
by Zacks Equity Research
Pfizer Inc. (PFE) announced data from its phase II study, ABRAZO, which is evaluating talazoparib in advanced breast cancer patients with germline BRCA 1/2 positive (gBRCA+) mutations, showing anti-tumor activity
Pfizer (PFE) Down 2.5% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pfizer's Kidney Cancer Drug Gets Acceptance in the U.S. & EU
by Zacks Equity Research
Pfizer Inc. (PFE) announced encouraging news with the FDA and the European Medicines Agency (EMA) accepting the company's regulatory submission for label expansion of its cancer drug, Sutent (sunitinib).
Pharma Stock Roundup: Positive Data from Lilly & Teva, BMY's Deals & More
by Arpita Dutt
Lilly (LLY) posted positive data on Cyramza while Teva's migraine drug delivered positive results in a late-stage study.
Pfizer's Trumenba Vaccine Approved by European Commission
by Zacks Equity Research
Pfizer Inc. (PFE) announced that its Trumenba vaccine received approval from the European Commission (EC) for active immunization of people aged 10 years and older for the prevention of invasive disease caused by Neisseria meningitidis serogroup B (MenB).
Pfizer's Epogen Biosimilar Gets Positive FDA Committee Vote
by Zacks Equity Research
Pfizer, Inc. (PFE) announced that an FDA advisory committee has recommended approval of its biosimilar version of ESA Epogen and Procrit.
Celldex's Immuno-Oncology Pipeline Continues to Impress
by Zacks Equity Research
On May 25, we issued an updated research report on Hampton, NJ-based Celldex Therapeutics, Inc. (CLDX).
Pharma Stock Roundup: Label Expansion for Merck Drug, Aerie Up On Eye Data
by Arpita Dutt
Merck (MRK) got another approval for Keytruda while Aerie shot up on positive data.
Aerie's Ophthalmic Candidate Positive in Registration Trial
by Zacks Equity Research
Aerie Pharmaceuticals, Inc. (AERI) announced positive primary efficacy results of the 90-day phase III registration trial -- Mercury 2 -- for its pipeline candidate Roclatan.
Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has approved their pipeline candidate sarilumab to be marketed under the trade name of Kevzara.
Shire (SHPG) Up on Positive Phase III Study Data on HAE Drug
by Zacks Equity Research
Shire plc (SHPG) announced positive top-line results from the phase III study, HELP, on HAE candidate, lanadelumab.
Merck's (MRK) Keytruda Gets FDA Nod for Two New Indications
by Zacks Equity Research
Merck & Co., Inc. (MRK) announced that the FDA has approved two new indications for Keytruda (pembrolizumab), the company's anti-PD-1 therapy.
Merck KGaA (MKGAF) Q1 Earnings Fall Y/Y, Revenues Increase
by Zacks Equity Research
Merck KGaA (MKGAF) reported first-quarter 2017 earnings of $1.28 per American Depositary Share, 14.7% lower than the year-ago figure of $1.50.
Endocyte (ECYT) Focused on Two Lead Pipeline Candidates
by Zacks Equity Research
We issued an updated report on Endocyte, Inc. (ECYT) on May 17.
J&J (JNJ) Plans to Seek Approval for 10 New Drugs by 2021
by Zacks Equity Research
Johnson & Johnson, Inc. (JNJ) discussed its future plans and showcased a strong pipeline of transformational medicines at a meeting held yesterday with industry analysts.
The Zacks Analyst Blog Highlights: Pfizer, Home Depot, ConocoPhillips, Prudential Financial and Canadian Pacific
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Home Depot, ConocoPhillips, Prudential Financial and Canadian Pacific
Sangamo's (SGMO) Hemophilia A Drug Gets Fast-Track Status
by Zacks Equity Research
Sangamo Therapeutics, Inc. (SGMO) announced that the FDA has granted fast track designation to pipeline candidate, SB-525.
5 Reasons Why Merck (MRK) is a Good Stock to Buy Now
by Zacks Equity Research
It looks like a great stock to buy now.
Stock Market Today & Home Depot, Pfizer and ConocoPhillips Research Reports
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Home Depot (HD) and ConocoPhillips (COP).
Aerie's (AERI) Rhopressa NDA Sufficient for FDA Review
by Zacks Equity Research
Aerie Pharmaceuticals, Inc. (AERI) announced that it has received notification from the FDA about the completion of the initial 60-day review of the NDA for Rhopressa
What's in Store for Merck KGaA (MKGAF) in Q1 Earnings?
by Zacks Equity Research
Merck KGaA (MKGAF) is scheduled to report first-quarter 2017 earnings results on May 18.
Pharma Stock Roundup: Mylan, Teva Q1 Earnings, Roche Drug Misses in Pivotal Study
by Arpita Dutt
While companies like Mylan (MYL), Allergan and Teva reported Q1 results this week, several companies provided updates on their cancer drugs.
Model N (MODN) Q2 Loss Narrower than Expected, Guides Well
by Zacks Equity Research
Model N, Inc. (MODN) reported second-quarter 2017 adjusted loss of 25 cents per share, which was wider than the year-ago quarter's loss of 21 cents.
Pharma Stock Roundup: Merck, Pfizer Report Q1 Earnings, J&J Talc Powder Lawsuit
by Arpita Dutt
Major pharma companies like Pfizer (PFE) and Merck reported Q1 results last week.